The Association between Plasma miRNA-21 Levels with Overall 1-year Survival Rate of Breast Cancer Patients at Various Stages

Authors

  • Pradana Zaky Romadhon 1. Department of Internal Medicine, Airlangga University, Faculty of Medicine, Surabaya, Indonesia 2. Universitas Airlangga Hospital, Surabaya, Indonesia 3. Dr. Soetomo General Teaching Hospital, Surabaya, Indonesia http://orcid.org/0000-0001-9306-5425
  • Ami Ashariati Prayoga 1. Department of Internal Medicine, Airlangga University, Faculty of Medicine, Surabaya, Indonesia 2. Universitas Airlangga Hospital, Surabaya, Indonesia 3. Dr. Soetomo General Teaching Hospital, Surabaya, Indonesia
  • Siprianus Ugroseno Yudho Bintoro 1. Department of Internal Medicine, Airlangga University, Faculty of Medicine, Surabaya, Indonesia 2. Dr. Soetomo General Teaching Hospital, Surabaya, Indonesia
  • Muhammad Noor Diansyah 1. Department of Internal Medicine, Airlangga University, Faculty of Medicine, Surabaya, Indonesia 2. Universitas Airlangga Hospital, Surabaya, Indonesia 3. Dr. Soetomo General Teaching Hospital, Surabaya, Indonesia
  • Putu Niken Amrita 1. Department of Internal Medicine, Airlangga University, Faculty of Medicine, Surabaya, Indonesia 2. Dr. Soetomo General Teaching Hospital, Surabaya, Indonesia
  • Merlyna Savitri 1. Department of Internal Medicine, Airlangga University, Faculty of Medicine, Surabaya, Indonesia 2. Dr. Soetomo General Teaching Hospital, Surabaya, Indonesia
  • Choirina Windradi Universitas Airlangga Hospital, Surabaya, Indonesia

Keywords:

miRNA-21, breast cancer, mortality rate, survival, health

Abstract

Background: miRNA 21 exhibits an increased expression in breast cancer (BC). However, its relationship with the 1-year survival of breast cancer patients is still disputable and under serious discussion. Methods: Cohort prospective study involving 49 breast cancer patients was done, comprising 26 in early stage and 23 in end-stage. We evaluated miRNA-21 values and observed its association with mortality within 1 year. Results: In general, there was a correlation between the increase in miRNA-21 levels and the mortality rate of breast cancer patients (r = 0.651; p <0.05). In the early stages, the increase in miRNA-21 values was not associated with breast cancer mortality (r= 0.25; p=0.218), but in the later stages, we found that the increase in miRNA-21 had a correlation with mortality (r=0.866; p=<0, 05). In advanced stage, high level of miRNA-21 had high asscociation with mortality rate (HR 17,27 95%CI 7,37-40,69). Conclusion: The increase in miRNA-21 values is associated with the 1-year survival of breast cancer patients.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2018;68(6):394-424.

Kemenkes. Kementrian Kesehatan RI: ‘Situasi Penyakit Kanker Indonesia’2015.

UK. Office of National Statistics: Cancer survival by stage at diagnosis for England 2019. Available from: https://www.gov.uk/government/statistics/cancer-survival-in-england-for-patients-diagnosed-between-2014-and-2018-and-followed-up-until-2019/cancer-survival-in-england-for-patients-diagnosed-between-2014-and-2018-and-followed-up-to-2019.

Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. International J Clin Oncol. 2008;13(5):447-51.

Gao J, Zhang Q. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. 2013.

Stieber P, Nagel D, Blankenburg I, et al. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer—A retrospective analysis of kinetics on 743 breast cancer patients. Clin Chim Acta. 2015;448:228-31.

Mar-Aguilar F, Mendoza-Ramírez JA, Malagón-Santiago I, et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers. 2013;34(3):163-9.

Zhang J, Jiang C, Shi X, Yu H, Lin H, Peng Y. Diagnostic value of circulating miR-155, miR-21, and miR-10b as promising biomarkers in human breast cancer. Int J Clin Experiment Pathol. 2016;9(10):10258-65.

Kayani M, Kayani MA, Malik FA, Faryal R. Role of miRNAs in breast cancer. Asian Pac J Cancer Prev. 2011;12(12):3175-80.

Yan LX, Huang XF, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. Rna. 2008;14(11):2348-60.

Wang G, Wang L, Sun S, Wu J, Wang Q. Quantitative Measurement of Serum MicroRNA-21 Expression in Relation to Breast Cancer Metastasis in Chinese Females. Annals Lab Med. 2015;35(2):226-32.

Qian B, Katsaros D, Lu L, et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Res Treat. 2008;117(1):131-40.

Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle. 2011;10(3):507-17.

Aboussekhra A, Al-Khanbashi M, Caramuta S, et al. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment. Plos One. 2016;11(4):e0152032.

Elghoroury EA, ElDine HG, Kamel SA, et al. Evaluation of miRNA-21 and miRNA Let-7 as prognostic markers in patients with breast cancer. Clin Breast Cancer. 2018;18(4):e721-e6.

Cuk K, Zucknick M, Heil J, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer. 2013;132(7):1602-12.

Shah R. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol. 2014;5(3):283.

Sun Y-S, Zhao Z, Yang Z-N, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017;13(11):1387-97.

Lin C-H, Yap YS, Lee K-H, et al. Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population. JNCI: Journal of the National Cancer Institute. 2019;111(12):1298-306.

Dong G, Liang X, Wang D, et al. High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Med Oncol. 2014;31(7).

Fattah H, Mahmoud N, Elzoghby D, Matar M, El Shaer I. Clinical utility of circulating microRNA-21 in breast cancer. Egyptian J Hosp Med. 2018;71(4):2950-5.

Sakr HI, Khowailed AA, Al-Fakharany RS, Abdel-Fattah DS, Taha AA. Serum uric acid level as a predictive biomarker of gestational hypertension severity; A prospective observational case-control study. Reviews on recent clinical trials. 2020;15(3):227-39.

Abdulhussain MM, Hasan NA, Hussain AG. Interrelation of the circulating and tissue MicroRNA-21 with tissue PDCD4 expression and the invasiveness of Iraqi female breast tumors. Indian J Clin Biochem. 2017.

Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences. 2008;105(30):10513-8.

Kim Y-K. Extracellular microRNAs as biomarkers in human disease. Chonnam Med J. 2015;51(2):51.

Papadaki C, Stratigos M, Markakis G, et al. Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer. Breast Cancer Res. 2018;20(1).

Downloads

Published

2022-01-10

How to Cite

Romadhon, P. Z., Prayoga, A. A., Bintoro, S. U. Y., Diansyah, M. N., Amrita, P. N., Savitri, M., & Windradi, C. (2022). The Association between Plasma miRNA-21 Levels with Overall 1-year Survival Rate of Breast Cancer Patients at Various Stages. Acta Medica Indonesiana, 53(4), 432. Retrieved from https://actamedindones.org/index.php/ijim/article/view/1886

Issue

Vol. 53 No. 4 (2021): Acta Medica Indonesiana

Section

ORIGINAL ARTICLE

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.